What is Scipher Medicine?
Scipher Medicine operates at the intersection of biotechnology and data science, specializing in precision immunology. The company utilizes its proprietary Spectra platform to decode a patient's unique molecular disease signature, effectively matching individuals with the most efficacious treatment options. By providing actionable insights to payers, healthcare providers, and pharmaceutical partners, Scipher Medicine is actively disrupting the traditional trial-and-error approach to autoimmune disease management. Its business model is built upon the dual pillars of diagnostic commercialization and the generation of high-value molecular data, which serves as a critical asset for the discovery and development of next-generation therapeutics.
How much funding has Scipher Medicine raised?
Scipher Medicine has raised a total of $217.3M across 4 funding rounds:
Series B
$25M
Debt
$350K
Series C
$82M
Other Financing Round
$110M
Series B (2020): $25M with participation from Khosla Ventures, Tachyon Ventures, Northpond Ventures, Granpool Innovative Investments, and Optum Ventures
Debt (2020): $350K led by PPP
Series C (2021): $82M supported by Khosla Ventures, aMoon, Alumni Ventures, Northpond Ventures LLC, and Echo Health Ventures LLC
Other Financing Round (2022): $110M featuring Neuberger Berman, Cowen Healthcare Investments, Hitachi Ventures, Laurion Capital Management, and Monashee Investment Management
Key Investors in Scipher Medicine
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, focusing on breakthrough technologies across sectors including health, enterprise software, and robotics.
Neuberger Berman
An independent, employee-controlled global asset management firm providing a wide range of investment solutions to institutions and individual investors.
Optum Ventures
The venture capital arm of Optum, dedicated to investing in early-stage companies that aim to disrupt the healthcare status quo and improve patient care.
What's next for Scipher Medicine?
With the recent influx of capital, Scipher Medicine is poised to scale its operational infrastructure and deepen its strategic partnerships with major pharmaceutical entities. The focus will likely shift toward broadening the clinical utility of the Spectra platform, ensuring that its diagnostic solutions become a cornerstone of autoimmune care. Furthermore, the company is expected to leverage its growing repository of patient molecular data to drive internal R&D initiatives, potentially unlocking new therapeutic targets. As the firm matures, its ability to demonstrate clear health economic value to payers will be paramount in sustaining its competitive advantage and achieving long-term market leadership in the precision medicine landscape.
See full Scipher Medicine company page
